Inhibiting the nuclear exporter XPO1 and the antiapoptotic factor BCL2 is synergistic in XPO1 and SF3B1 mutant hematologic malignancies.

被引：0
|
作者：
Totiger, Tulasigeri M. [1 ]
Chaudhry, Sana [1 ]
Afaghani, Jumana [1 ]
Taylor, Justin [1 ]
机构：
[1] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1341
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Selinexor targeting XPO1 promotes PEG3 nuclear accumulation and suppresses cholangiocarcinoma progression
    Xiang, Deng
    Wang, Min
    Wu, Huajun
    Chen, Xi
    Chen, Tianxiang
    Yu, Dongshan
    Xiong, Lei
    Xu, Han
    Luo, Ming
    Zhang, Shouhua
    Wu, Linquan
    Yan, Jinlong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (05) : 669 - 683
  • [22] Synergistic effect of the combination of XPO1 and mTORC1/2 inhibition for the treatment of triple-hit DLBCL.
    Hou, Bing
    Wang, Aihua
    Shan, Bo
    Mei, Jay
    CANCER RESEARCH, 2021, 81 (13)
  • [23] Synthetic lethal targeting of TET2-mutant haematopoietic stem and progenitor cells by XPO1 inhibitors
    Jing, Chang-Bin
    Prutsch, Nicole
    He, Shuning
    Zimmerman, Mark W. W.
    Landesman, Yosef
    Look, A. Thomas
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 (03) : 489 - 501
  • [24] SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients
    Jeromin, S.
    Weissmann, S.
    Haferlach, C.
    Dicker, F.
    Bayer, K.
    Grossmann, V.
    Alpermann, T.
    Roller, A.
    Kohlmann, A.
    Haferlach, T.
    Kern, W.
    Schnittger, S.
    LEUKEMIA, 2014, 28 (01) : 108 - 117
  • [25] Acquisition of TP53 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients During the Course of Disease Is Associated with an Unmutated IGHV Status and Mutations in XPO1 and SF3B1
    Grossmann, Vera
    Kohlmann, Alexander
    Schnittger, Susanne
    Weissmann, Sandra
    Dicker, Frank
    Jeromin, Sabine
    Boeck, Lucia
    Alpermann, Tamara
    Kern, Wolfgang
    Haferlach, Torsten
    Haferlach, Claudia
    BLOOD, 2012, 120 (21)
  • [26] XPO1 Inhibitor Selinexor Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma Via Nuclear Retention of IκB
    Wang, Y. Lynn
    Ming, Mei
    Xie, Bingqing
    Sukhanova, Madina
    Wang, Weige
    Kadri, Sabah
    Sharma, Shruti
    Lee, Jimmy
    Shacham, Sharon
    Landesman, Yosef
    Maltsev, Natalia
    Lu, Pin
    BLOOD, 2017, 130
  • [27] SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients
    S Jeromin
    S Weissmann
    C Haferlach
    F Dicker
    K Bayer
    V Grossmann
    T Alpermann
    A Roller
    A Kohlmann
    T Haferlach
    W Kern
    S Schnittger
    Leukemia, 2014, 28 : 108 - 117
  • [28] 4-Hydroxy-2-nonenal causes nuclear accumulation of p62 by inhibiting Xpo1 and promoting the proteolytic pathway in the nucleus
    Kayama, Emi
    Baoshuo, Ning
    Tatsuno, Rinna
    Nishi, Kanako
    Mohammed, Elsayed S. I.
    Abiko, Yumi
    Yanagawa, Toru
    Takahashi, Satoru
    Warabi, Eiji
    PLOS ONE, 2025, 20 (02):
  • [29] Oncogenic Mutations in XPO1 Promote Lymphoid Transformation By Altering Nuclear/Cytoplasmic Localization of NFκB Signaling Intermediates
    Taylor, Justin
    Zhang, Xiao Jing
    Paffenholz, Stella V.
    Penson, Alexander V.
    Chang, Matthew
    Marcelus, Christina
    Bitner, Lillian E.
    Chung, Young Rock
    Yoshimi, Akihide
    Lee, Stanley Chun-Wei
    Boukhali, Myriam
    Soni, Rajesh K.
    Hendrickson, Ronald C.
    Taylor, Barry S.
    Rodriguez, Jose A.
    Haas, Wilhelm
    Abdel-Wahab, Omar
    BLOOD, 2017, 130
  • [30] The XPO1 Inhibitor KPT-8602 Ameliorates Parkinson's Disease by Inhibiting the NF-?B/NLRP3 Pathway
    Liu, Shuhan
    Wang, Shengxiang
    Gu, Runze
    Che, Na
    Wang, Jing
    Cheng, Jinbo
    Yuan, Zengqiang
    Cheng, Yong
    Liao, Yajin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
12345